Dual-Agonist Peptides: GLP-1 and GIP in Research
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
- This overview explains dual agonist peptides like tirzepatide that act on two metabolic receptors (GIP and GLP-1) at once.
- In human trials, investigators reported that engaging both receptors was linked to strong weight and blood-sugar changes; tirzepatide is FDA-approved (Mounjaro/Zepbound).
- The reporting here is about the published research, not a BioRegen claim, and online discussion is unverified anecdote.
- Nothing here is approved by BioRegen for human use or is medical advice.
- BioRegen sells these strictly for laboratory and educational research.
Some peptides are built to switch on two body signals at the same time: GLP-1 and GIP. Both of these signals help the body manage blood sugar and appetite. Peptides that hit both at once are a hot topic in metabolic research right now. This page explains, in plain terms, what these peptides are and what the research says about them. All information is for laboratory and educational research only. These compounds are not approved for human or veterinary use, and nothing here is medical advice.
What a dual agonist is
An agonist is something that turns a signal on. A "dual agonist" turns on two signals at once. Here, those two signals are GLP-1 and GIP. The most-studied peptide of this kind is tirzepatide. Review papers describe it as a peptide that switches on both the GIP and GLP-1 signals [2]. In one clinical trial, called SURPASS-1, researchers reported that higher amounts produced larger effects on the body's handling of blood sugar compared with a placebo (a dummy with no active ingredient) [1]. In general, the research suggests that turning on two signals tends to produce wider effects on the body's metabolism than turning on just one. The strength of this evidence is still being studied.
How it compares to triple agonists
Some peptides go a step further and turn on three signals instead of two. Retatrutide is one example. It adds a third signal called glucagon. For a side-by-side look, see our retatrutide vs tirzepatide vs semaglutide comparison.
Selected research references
- [1] Rosenstock J, et al. (2021). Efficacy and safety of tirzepatide in type 2 diabetes (SURPASS-1). Lancet. doi:10.1016/S0140-6736(21)01324-6
- [2] Nauck MA, D'Alessio DA (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist. Cardiovasc Diabetol. doi:10.1186/s12933-022-01604-7
Reference metadata sourced via PubMed.
Explore metabolic research compounds in our BURN collection. Join the research list for 10% off your first order by creating a free account.
Disclaimer: All products and information provided by BioRegen are for laboratory and educational research purposes only. Nothing here is medical advice, and none of these compounds are approved for human or veterinary use.